“As we look at it, we do expect you will see a flattening of the curve as we see the female indication, be more fully penetrated. Obviously, more to go there, given what we believe is still the addressable population. And then it will ramp back to growth as the male population comes on in full.”

How to check this claim

Look at: Growth trajectory pattern of the relevant product/vaccine revenue (e.g., HPV vaccine sales such as Gardasil), specifically a deceleration/flattening followed by re-acceleration

It came true if: Year-over-year revenue growth rate for the product decelerates toward roughly 0% (flattening) in nearer-term periods, then re-accelerates to a clearly positive growth rate (>5% YoY) in a later period before 2030

Where: Company-disclosed segment/product revenue in quarterly earnings releases and 10-K/10-Q filings

Verify independently

SEC filings for MRK ↗ · Claim quote is verbatim from the 2024Q2 earnings call.